Inhibikase Therapeutics Inc美股招股说明书(2025-12-19版)

PROSPECTUS SUPPLEMENT(To prospectus dated June27, 2025) Up to $185,000,000 Common Stock We have previously entered into an Open Market Sale AgreementSM(the “sales agreement”), dated June20, 2025, with Jefferies LLC(“Jefferies”), relating to the sale of shares of our common stock, par value $0.001 per share. In accordance with the terms of the salesagreement, pursuant to this prospectus supplement, we may offer and sell shares of our common stock having an aggregate offering priceof up to $185,000,000 from time to time through Jefferies, acting as our sales agent. Our common stock is listed on the Nasdaq Capital Market under the symbol “IKT.” On December17, 2025, the last reported sale price ofour common stock on the Nasdaq Capital Market was $1.59 per share. Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an “at the market offering” asdefined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Jefferies is not required to sellany specific number or dollar amount of securities, but will act as sales agent using commercially reasonable efforts consistent with itsnormal trading and sales practices, on mutually agreed terms between us and Jefferies. There is no arrangement for funds to be received Jefferies will be entitled to a compensation under the terms of the sales agreement at a commission rate of up to 3.0% of the grossproceeds of any shares of common stock sold under the sales agreement. In connection with the sale of our common stock on our behalf,Jefferies will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Jefferies will be deemedto be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect tocertain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Investing in our common stock involves a high degree of risk. See the information contained under “Risk Factors” beginning onpage S-8 of this prospectus supplement and the documents incorporated by reference herein. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminaloffense. Jefferies The date of this prospectus supplement is December19, 2025. Table of Contents PROSPECTUS SUPPLEMENT INCORPORATION BY REFERENCE Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the“SEC”), using a “shelf” registration process. Under this registration statement, we may offer up to $300,000,000 of our securities. Under thisprospectus supplement, we may offer shares of our common stock having an aggregate offering price of up to $185,000,000 from time to time atprices and on terms to be determined by market conditions at the time of offering. The $185,000,000 of shares of our common stock that may be Before buying any of the shares of our common stock offered hereby, we urge you to carefully read this prospectus supplement, together with theinformation incorporated by reference in this prospectus supplement, and any free writing prospectus or prospectus supplement that we haveauthorized for use in connection with this offering when making your investment decision. You should also read and consider the information inthe documents we have referred you to under the headings “Where You Can Find More Information” and “Incorporation of Certain Information by This prospectus supplement describes the terms of this offering of common stock and also adds to and updates information contained in thedocuments incorporated by reference into this prospectus supplement. To the extent there is a conflict between the information contained in thisprospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this prospectussupplement that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information inthis prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date You should rely only on the information contained in or incorporated by reference in this prospectus supplement, and any free writing prospectusor prospectus supplement that we have authorized for use in connection with this offering. We have not, and the sales agent has not, authorizedanyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the sales agent is not, making an offer to sell these se